TGV
RAPP

TRV GP V’s Rapport Therapeutics RAPP Stock Holding History

TRV GP V’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$262M Sell
6,280,525
-854,708
-12% -$31.4M 52.53% 1
2026
Q1 		$223M Hold
7,135,233
– – 55.68% 1
2025
Q4 		$216M Hold
7,135,233
– – 50.44% 1
2025
Q3 		$212M Hold
7,135,233
– – 59.95% 1
2025
Q2 		$81.1M Hold
7,135,233
– – 48.98% 1
2025
Q1 		$71.6M Hold
7,135,233
– – 57.21% 1
2024
Q4 		$127M Buy
+7,135,233
New +$158M 43.06% 2

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TRV GP V's RAPP Position: Q2 2026 in Review

TRV GP V reduced its Rapport Therapeutics (RAPP) stake by 12% in Q2 2026, selling an estimated $31.4M and leaving 6,280,525 shares worth $262M. The position accounts for 52.53% of the portfolio, ranked #1.

TRV GP V first reported a position in RAPP in Q4 2024 and has held it in 7 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • TRV GP V held 6,280,525 shares of Rapport Therapeutics worth $262M as of Q2 2026.
  • TRV GP V sold 854,708 Rapport Therapeutics shares in Q2 2026, an estimated $31.4M.
  • Rapport Therapeutics made up 52.53% of TRV GP V's portfolio in Q2 2026, its #1 holding.
  • TRV GP V first reported a position in Rapport Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on TRV GP V's 13F filing for Q2 2026, filed 10 Aug 2026.